Get in Touch

We identified optimal cost-efficient routes to market for an autologous GT for an ultra-rare indication ​

  • Access Strategy, Digital Solutions
P4A found us a solution that enables EU ​ patients to access our gene therapy ​ without breaking the bank
Chief​ Commercial​ Officer​

Client Challenge

Goal was to find an optimal ​route-to-market for Europe for an GT targeting an ultra-rare condition​

Gene therapy launch for a biotech ​client planned for 2021 in Europe

The autologous GT targeted a small ​patient population with a prevalence ​< 100 patients in Europe

Client was financially and personnel constrained, but were mandated to commercialise in-house by investors​

P4A Solution

P4A reviewed the data and ​recommended the biotech ​implemented the following: ​

  • Pathway Mapping​
  • Payer & KOL research to ​identify pathway barriers​
  • NPV modelling of ​different launch options​
  • Follow-up recommendations ​ ​

The Successful Outcome​

  • Identified paid for named patient access routes, including import pathways or cross-border pathways in all EU markets ​
  • Defined treatment site selection strategy and shortlist of potential EU centres​
  • Formulated the materials and services that support physicians in making a request to access treatment for their named patient ​

Need more details?

Do you want to learn more about the successful outcome for this case study? Are you interested in P4A Services or just want to say Hi?

get in touch

Explore other case studies

Understand evidence requirements beyond clinical trial data for launching an orphan drug in Türkiye & the GCC

  • Access Strategy

Optimising the PRMA potential of an orphan oncology asset in EU4 + UK and Japan

  • Access Strategy, Price Optimisation
p4a-logo-small-retina-white

We are award winning global experts in access for orphan drugs and Cell and Gene Therapies.

Twitter Instagram Youtube Linkedin

About

Services

Insights

Case Studies

Contact

P4A Services

For all access and Rare Disease related overview enquiries